Telotristat etiprate showed clinical benefit in treating carcinoid syndrome in cancer patients not adequately controlled by long-acting somatostatin analog therapy, the current standard of care, according to data from the phase III TELESTAR study.
Elizabeth Comen originally set out to write a book about the wellness industry, but ended up writing a different book altogether.
